ALSO NOTED: Flamel inks licensing deal;Alfacell trial hits a milestone; and much more...

> France's Flamel Technologies gets an undisclosed upfront payment and a schedule of potential milestone payments after signing a licensing and development deal with Wyeth for using its technology to deliver a marketed protein. Release

> Alfacell Corporation has confirmed that 290 evaluable events--patient deaths--have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for unresectable malignant mesothelioma. Release

> Prana Biotechnology has raised $7 million in a private placement. Release

> What's a generic drug company to do? A federal judge refused Wyeth's request for an injunction against the launch generic Protonix, and Teva could start selling. But if Wyeth wins the patent case, then Teva would have to fork over three times its sales. Report

> An outbreak of foot-and-mouth disease in the UK has been contained after a government report pinned the blame for the outbreak on leaky pipes at the Institute for Animal Health's Pirbright site. Report

> The NIH has doled out $438 million for daring research projects. Report

> And Finally... Venture capitalists bet big on nanotechnology. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.